Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR BPA study: Balloon Pulmonary Angioplasty vs Riociguat in Inoperable CTEPH
jRCTs031180239Completed
- Sponsor
- Bayer
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) (2 arms), sponsored by Bayer. Primary endpoint: Change in mean pulmonary artery pressure from baseline to 12 months. Started Apr 2016; status: completed.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on jRCTs031180239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180239.